» Articles » PMID: 12591679

Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma: Usefulness of Coded Phase-inversion Harmonic Sonography

Overview
Specialties Oncology
Radiology
Date 2003 Feb 20
PMID 12591679
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The purpose of our study was to assess the value of coded phase-inversion harmonic sonography performed approximately 1 week after the patients had undergone transcatheter arterial chemoembolization with iodized oil for hepatocellular carcinoma.

Subjects And Methods: We studied 40 patients with 44 nodules measuring 1.5-11.0 cm in diameter (mean +/- SD, 3.9 +/- 2.0 cm) who underwent transcatheter arterial chemoembolization. Coded phase-inversion harmonic sonography, a technique based on a combination of phase-inversion harmonics and coded technology, was performed with a contrast agent approximately 1 week after chemoembolization. The results were compared with those obtained using dynamic CT (n = 44 lesions) and dynamic MR imaging (n = 20 lesions). We also evaluated the recurrence of hepatocellular carcinoma during clinical follow-up in 17 patients who did not undergo additional local therapy.

Results: The detection rates of intratumoral vascularity of coded phase-inversion harmonic sonography, dynamic CT, and dynamic MR imaging were, respectively, 38 (86%) of 44 lesions, 19 (43%) of 44 lesions, and 10 (50%) of 20 lesions. Of 19 nodules of hepatocellular carcinoma treated only by transcatheter arterial chemoembolization, 17 nodules showed enhancement on coded phase-inversion harmonic sonography, suggesting incomplete responses. In all 17 nodules, apparent recurrence was noted on dynamic CT during clinical follow-up, even in nodules that had been observed to be completely filled with iodized oil 1 week after the chemoembolization.

Conclusion: We found coded phase-inversion harmonic sonography to be highly sensitive and accurate for evaluating the treatment response in patients with hepatocellular carcinoma even shortly after treatment. Consequently, it allows early recognition of the need for additional local ablation therapy and estimation of the risk of hepatocellular carcinoma recurrence.

Citing Articles

Diagnostic values of contrast-enhanced MRI and contrast-enhanced CT for evaluating the response of hepatocellular carcinoma after transarterial chemoembolisation: a meta-analysis.

Zhang C, Chen X, Wang J, Luo T BMJ Open. 2024; 14(4):e070364.

PMID: 38580362 PMC: 11002368. DOI: 10.1136/bmjopen-2022-070364.


Contrast-enhanced US Evaluation of Hepatocellular Carcinoma Response to Chemoembolization: A Prospective Multicenter Trial.

Savsani E, Shaw C, Forsberg F, Wessner C, Lyshchik A, OKane P Radiology. 2023; 309(1):e230727.

PMID: 37847138 PMC: 10623205. DOI: 10.1148/radiol.230727.


Loco-regional treatment of hepatocellular carcinoma: Role of contrast-enhanced ultrasonography.

Inzerillo A, Meloni M, Taibbi A, Bartolotta T World J Hepatol. 2022; 14(5):911-922.

PMID: 35721286 PMC: 9157715. DOI: 10.4254/wjh.v14.i5.911.


Meta-analysis and systematic review of contrast-enhanced ultrasound in evaluating the treatment response after locoregional therapy of hepatocellular carcinoma.

Hai Y, Savsani E, Chong W, Eisenbrey J, Lyshchik A Abdom Radiol (NY). 2021; 46(11):5162-5179.

PMID: 34410432 PMC: 8569603. DOI: 10.1007/s00261-021-03248-9.


Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies.

Eisenbrey J, Gabriel H, Savsani E, Lyshchik A Abdom Radiol (NY). 2021; 46(8):3579-3595.

PMID: 33825927 PMC: 8569604. DOI: 10.1007/s00261-021-03059-y.